-
●Establishing Special Project ●
On February 10, 2020, Jiangsu Provincial Administration of Traditional Chinese Medicine decided to formally establish a special emergency research project, “Clinical Research on TCM Syndrome Law and Differentiated Treatment Plans of COVID-19”, mainly in a bid to implement the scientific research requirements of COVID-19 prevention and treatment with integrated traditional Chinese and Western medicine, to better refine TCM-based COVID-19 prevention and treatment plans, to solve the emergency needs through synchronous research and production, and to provide clinical scientific research support for epidemic prevention and control.
●Responsible Institutions ●
According to the authorization, this project consisting of 6 sub-projects are jointly implemented by the 6 hospitals of Nanjing University of Traditional Chinese Medicine, Nanjing Second Hospital, Xuzhou Infectious Disease Hospital, Changzhou Third People’s Hospital, Suzhou Fifth People’s Hospital and Nantong Third People’s Hospital, with Nanjing University of Traditional Chinese Medicine as organizer and Professor Cheng Haibo as project leader. Tianjiang Pharmaceutical is responsible for providing drugs for scientific research.
●Drug Preparations for Scientific Research ●
Nanjing University of Traditional Chinese Medicine quickly organized a team leading by the TCM master Zhou Zhongying to carry out rapid scientific research under the special emergency research project established by Jiangsu Provincial Administration of Traditional Chinese Medicine. The research team developed preventive granules for close contacts, medical staff and susceptible people, Huosu Granules for patients in the early stage of pneumonia, as well as Modified Huosu Granules and Xuanfei Huashi Granules for patients in the middle stage of pneumonia.
After receiving the notification of the task of providing drugs for scientific research, Tianjiang Pharmaceutical quickly organized the personnel of scientific research, production and marketing to produce drugs according to the requirements of the project team. The first batch of drugs the company manufactured included 3,000 boxes of treatment drugs (Huosu Granules, Modified Huosu Granules, Xuanfei Huashi Granules) and 10,000 boxes of preventive granules, and the treatment drugs have been successively sent to the 5 hospitals responsible for clinical research.
When an epidemic breaks out, a command is issued. It is our responsibility to prevent and control it. In the face of the epidemic, Tianjiang Pharmaceutical will spare no efforts to continue cooperating with Nanjing University of Traditional Chinese Medicine on the scientific research into COVID-19 prevention and treatment with integrated traditional Chinese and western medicine. While ensuring the production and timely supply of drugs for scientific research, Tianjiang Pharmaceutical Institute will actively work with the project team and all implementing institutions to follow up clinical research and to timely summarize the clinical effects and safety of TCM in COVID-19 treatment and prevention, in an effort to strongly support the epidemic prevention and treatment and to contribute to the anti-epidemic scientific research.
Prevention
Preventive Granules: light and clear, nourishing the lung, and dispelling filth with aroma
Pseudostellariae Radix (10g), Adenophorae Radix (10g), Perillae Folium (6g), Schizonepetae Herba (6g), Pogostemonis Herba (6g), Chrysanthemi Indici Flos (10g), Paridis Rhizoma (6g).
In the early stage: syndrome of dampness retention in the exterior and interior
Huosu Granules: Pogostemonis Herba (15g), Perillae Folium (15g), Sojae Semen Praeparatum (15g), Atractylodis Rhizoma (15g), Magnoliae Officinalis Cortex (10g), Peucedani Radix (15g), Bupleuri Radix (15g), Scutellariae Radix (10g), Artemisiae Annuae Herba (20g), Armeniacae Semen Amarum (10g), Notopterygii Rhizoma Et Radix (10g), Lonicerae Japonicae Flos (15g), Forsythiae Fructus (15g).
In the middle stage: syndrome of lung blockage with heat-toxin
Modified Huosu Granules: Pogostemonis Herba (15g), Sojae Semen Praeparatum (15g), Sojae Semen Praeparatum (15g), Atractylodis Rhizoma (15g), Magnoliae Officinalis Cortex (10g), Peucedani Radix (15g), Bupleuri Radix (15g), Scutellariae Radix (10g), Artemisiae Annuae Herba (20g), Armeniacae Semen Amarum (10g), Lonicerae Japonicae Flos (15g), Forsythiae Fructus (15g), Ephedrae Herba Praeparata Cum Melle(6g), Gypsum Fibrosum (30g), Rhei Radix Et Rhizoma (6g), Glycyrrhizae Radix Et Rhizoma (6g).
In the middle stage: syndrome of lung blockage with dampness-toxin
Xuanfei Huashi Granules: Ephedrae Herba Praeparata (9g), Armeniacae Semen Amarums (10g), Mori Cortex (30g), Descurainiae Semen Lepidii Semen (20g), Benincasae Semen (20g), Pinelliae Rhizoma Praeparatum (10g), Magnoliae Officinalis Cortex (10g), Perillae Fructus (15g), Sinapis Semen (10g), Trichosanthis Pericarpium (15g), Inulae Flos (9g), Cyperi Rhizoma (10g), Curcumae Radix (10g), Persicae Semen (10g), Astragali Radix (20g)
About Zhou Zhongying: Zhou Zhongying serves as Professor, Chief Physician, Doctoral Supervisor of Nanjing University of Traditional Chinese Medicine. He is a leader of provincial key discipline of TCM therapies for acute and difficult internal diseases. He is selected as TCM Master in China’s First TCM Master Evaluation and known as the Famous Senior TCM Doctor in Jiangsu. He is also a member of the Expert Advisory Committee of the National Administration of Traditional Chinese Medicine, one of the first batch of recipients of State Council government special allowance, a national outstanding graduate teacher, and an advanced science and technology worker in national institutions of higher education. Zhou Zhongying has successively directed and undertaken 37 research topics, won 22 scientific and technological progress awards above the provincial level, edited and assisted the editing of 27 textbooks on TCM internal medicine, and published over 100 academic papers.